A trial to see the effects of increased doses of ACP-196 (the test drug) in subjects with Leukemia • Establish the safety and the MTD of orally administered acalabrutinib in subjects with CLL/SLL • Determine the PK of orally administered acalabrutinib and identification of its major metabolite

• Country None
• organs None
• Specialty None

A Trial to See the Effects of ACP-196 (the test drug) in Patients who have Mantle Cell Lymphoma Estudio para ver los efectos de ACP-196 ( el fármaco del estudio) en pacientes con linfoma de células del manto To determine the activity of ACP-196 in subjects with relapsed or refractory MCL as measured primarily by response rate. In addition, activity of ACP-169 will be assessed by duration of response, prog...

• Country None
• organs None
• Specialty None

A Clinical trial to compare standard of care treatment: Nab-Paclitaxel/Gemcitabine alone or in combination with ACP-196 in patients with previously untreated Metastatic Pancreatic Cancer To evaluate the efficacy of ACP-196 and nab-paclitaxel/gemcitabine based on ORR in subjects with metastatic pancreatic cancer using standard response criteria

• Country None
• organs None
• Specialty None

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma To evaluate the efficacy of acalabrutinib (ACP-196) in combination with bendamustine and rituximab (BR) compared with placebo in combination with BR based on Independent Review Committee (IRC) asses...

• Country None
• organs None
• Specialty None

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B), based on IRC assessment of PFS per IWCLL 2008 cr...

• Country None
• organs None
• Specialty None

A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisib/Rituximab alone in patients with with Relapsed or Refractory Chronic Lymphocytic Leukemia To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression...

• Country None
• organs None
• Specialty None

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy To check the efficacy of ACP-196 in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy

• Country None
• organs None
• Specialty None